Edition:
United Kingdom

China NT Pharma Group Co Ltd (1011.HK)

1011.HK on Hong Kong Stock

1.16HKD
16 Nov 2018
Change (% chg)

-- (--)
Prev Close
HK$1.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,182,646
52-wk High
HK$2.48
52-wk Low
HK$1.12

Summary

Name Age Since Current Position

Tit Ng

51 Executive Chairman of the Board, Chief Executive Officer

Fei Wang

41 2018 Chief Financial Officer

Baoming Ge

49 General Manager of Corporate Development and Product Research and Development Centre

Yu Chin

51 2015 Executive Director

Weizhong Wu

45 2015 Executive Director

Biao Gui

53 2014 Director of Sales, Director of Marketing

Siu Kuen Lai

2018 Company Secretary

Jianying Lou

54 2017 Non-Executive Director

Wei Qian

58 2010 Non-Executive Director

Yan Hong

52 2018 Independent Non-Executive Director

Patrick Sun

59 2010 Independent Non-Executive Director

Tze Shan Hailson Yu

60 2017 Independent Non-Executive Director

Biographies

Name Description

Tit Ng

Mr. Ng Tit serves as Executive Chairman of the Board, Chief Executive Officer of China NT Pharma Group Co Ltd. He is the co-founder of Group, is Chairman and has been Chief Executive Officer since 1995. Mr. Ng was appointed as the Company’s Executive Director on 1 March 2010. Mr. Ng is a member of the Tenth Jiangsu Committee of the Chinese People’s Political Consultative Conference of the PRC. Mr. Ng is responsible for the overall strategic planning and management of Group. Mr. Ng has experience in the pharmaceutical industry, having been engaged in the pharmaceutical business for over 15 years. Mr. Ng and Ms. Chin entered the pharmaceutical business in 1995 after considering the growth potential of the pharmaceutical business in China. Prior to establishing the Group in 1995, Mr. Ng was the deputy general manager of Guiyang Miracle Plaza Hotel from 1988 to 1991. Mr. Ng obtained his Bachelor of Philosophy from Guizhou University in 1986. In 2007, Mr. Ng obtained an Executive Master of Business Administration from Fudan University and was also given the Outstanding Dissertation Award by the Department of Management, Fudan University.

Fei Wang

Mr. Wang Fei is Chief Financial Officer of the Company. Mr. Wang is a Chinese certified public accountant, and has accumulated nearly 20 years of extensive experience in audit, accounting and financial management. Before joining the Company, Mr. Wang worked in AstraZeneca, an international pharmaceutical company, as the chief financial officer of China operation. He was also an independent director Xinjiang Tianye Co., of a company whose A shares were listed on the Shanghai Stock Exchange from March 2013 to October 2016 and a director of Yanchuang Applied Materials (Ganzhou) Inc. Ltd, a company listed on National Equities Exchange and Quotations from October 2016 to November 2017. Mr. Wang graduated from Xinjiang University of Finance and Economics majoring in corporate finance management in 1999 and obtained from Shanghai Jiao Tong University and Euromed Marseille Ecole de Management a master degree majoring in business administration in 2012.

Baoming Ge

Mr. Ge Baoming serves as General Manager of Corporate Development and Product Research and Development Centre of the Company. He has been appointed as the General Manager of Corporate Development and Product Research and Development Centre as well as the Clinical Medicine Director of the Marketing and Sales Centre of the Group. He is responsible for business development, development of new pharmaceutical products and research and management of clinical medicine. Mr. Ge has over 15 years of experience in operating and managing the Research and Development Centre, and has accumulated extensive experience in product introduction, registration, research and development and clinical medicine. Prior to joining the Group, Mr. Ge worked as director of research and development at various well-known pharmaceutical companies, including Rottapharm, Luye Pharma Group Limited and Shanghai Green Valley Pharmaceutical Co., Ltd.. Mr. Ge obtained his bachelor degree of Clinical Medicine from Beijing Medical University in 1990. He also obtained a master degree in Clinical Medicine from The University of Western Ontario in 2003.

Yu Chin

Ms. Chin Yu serves as Executive Director of China NT Pharma Group Co Ltd. She is a co-founder of the Group. Ms. Chin has been re-designated from non-executive Director to executive Director of the Group since 1 February 2015. Ms. Chin is responsible for the daily operations of NT Pharma (Hong Kong) Co., Ltd. Ms. Chin was appointed as non-executive Director on 1 March 2010. Prior to the establishment of the Group, Ms. Qian was an accounting professional. Ms. Chin worked in Bank of Communications from 1987 to 1993.

Weizhong Wu

Mr. Weizhong Wu serves as Executive Director of the Company. He obtained a bachelor’s degree in chemical engineering from Dalian University of Technology in 1992. He also obtained an EMBA from Fudan University in 2004. Mr. Wu has over 18 years of experience in pharmaceutical manufacturing. In 2000, he joined Suzhou First Pharmaceutical Co., Ltd (“Suzhou First”), a subsidiary of the Company, as a factory manager. In 2006, Mr. Wu was appointed as the general manager of Suzhou First and is currently the vice president of manufacturing. As the vice president of manufacturing, Mr. Wu is responsible for the overall operation of the Group’s manufacturing facilities. Prior to joining the Group, Mr. Wu worked at various positions including engineer, assistant manager and deputy factory manager of Suzhou No. 4 Pharmaceutical Factory from 1992 to 2000.

Biao Gui

Mr. Gui Biao serves as Director of Marketing and Sales Centre of the Company. He joined the Group in September 2014 to serve as Director of Marketing and Sales Centre of the Group. He is responsible for strategy development, market data analysis and academic promotion. Mr. Gui has over 18 years of marketing and management experience in multinational pharmaceutical companies. In recent years, he has been focusing on the sales and marketing of oncology products. Prior to joining the Group, he has worked for various multinational pharmaceutical companies, including Eisai China, Sanofi-aventis China, Novartis China, AstraZeneca China, Pharmacia & Upjohn (China) Ltd. and Pfizer, Inc., engaging in the product areas including oncology, CNS and anti-infective products. Between 1988 and 1994, Mr. Gui was a clinician in Renji Hospital of Shanghai Jiao Tong University. Mr. Gui obtained his bachelor degree in Clinical Medicine from Medicine School of Shanghai Jiao Tong University in 1988.

Siu Kuen Lai

Ms. Lai Siu Kuen is Company Secretary of the Company. Ms. Lai is an associate director of TMF Hong Kong Limited, which is a corporate secretarial services provider. She has over 18 years of professional and in-house experience in the company secretarial field. She is a fellow member of the Hong Kong Institute of Chartered Secretaries and the Institute of Chartered Secretaries and Administrators in the United Kingdom.

Jianying Lou

Ms. Lou Jianying is Non-Executive Director of the Company. She is a postgraduate. From January 1998 to January 2004, she served as the deputy general manager of Hualian Group Asset Trust Co., Ltd. From January 2004 to May 2011, she served as the deputy general manager, the chief financial officer, and the secretary of the board of directors of Shanghai No.1 Pharmacy Co., Ltd., a company listed on the Shanghai Stock Exchange (stock code: 600833). From May 2011 to May 2015, Ms. Lou served as the vice president and the secretary of the board of directors of Shanghai Jiao Da Onlly Co., Ltd., a company listed on the Shanghai Stock Exchange (stock code: 600530). From May 2015 to present, Ms. Lou serves as the vice president and the chief financial officer of Shanghai Jiao Da Onlly Co., Ltd..Ms. Lou has been a certified public accountant and a senior accountant in the PRC.

Wei Qian

Dr. Qian Wei serves as Non-executive Director of China NT Pharma Group Co Ltd., since March 1, 2010. Dr. Qian is currently a professor of Department of Electrical and Computer Engineering, University of Texas at EL Paso. Dr. Qian was appointed as Allen Henry Professor of Electrical Engineering in the Engineering College, Florida Institute of Technology in 2009. He had previously been an associate professor of Department of Interdisciplinary Oncology at Moffitt Cancer Center, College of Medicine, University of South Florida from 2001 to 2007. Dr. Qian obtained a bachelor’s degree in Engineering in 1982 and a master degree in Engineering in 1985, both from Nanjing University of Post and Telecommunications. He also obtained a doctorate degree in Engineering from Southeast University in 1990.

Yan Hong

Dr. Hong Yan is an Independent Non-Executive Director of the Company. He is a professor of finance at the Shanghai Advanced Institute of Finance (SAIF) of Shanghai Jiao Tong University, where he serves as the deputy dean as well as the deputy director of China Academy of Financial Research. He is also a director of the China Hedge Fund Research Center. Before he joined SAIF as a full-time teaching staff, Dr. Yan was a tenured faculty member at the Moore School of Business in the University of South Carolina, the United States of America. Previously, he was on the faculty at the University of Texas at Austin and was a visiting academic scholar at the Securities & Exchange Commission and the Federal Reserve of the United States. He was also a visiting professor of the University of Hong Kong and Cheung Kong Graduate School of Business. Dr. Yan holds a Doctor of Philosophy degree (Ph.D.) in Finance from the University of California, Berkeley, and also holds a Ph.D. in Applied Physics from the University of Michigan.

Patrick Sun

Mr. Xin Dinghua, also known as Patrick Sun, CPA is an Independent non-executive Director of China NT Pharma Group Co Ltd., since March 1, 2010. He was initially appointed as Independent Non-executive Director on 1 March 2010 for a term of one year and was subsequently re-appointed as Independent Non-executive Director on 7 March 2011 after expiry of the term of office. Mr. Sun was an Independent Non-executive Director of The Link Management Limited (the Manager of The Link Real Estate Investment Trust), listed on the Hong Kong Stock Exchange (stock code: 823) between September 2004 and July 2007. He was an Executive Director and Chief Executive Officer of Value Convergence Holdings Limited (stock code: 821), a company listed on the Hong Kong Stock Exchange, from August 2006 to October 2009. He was a member of the Takeovers & Mergers Panel and the Takeovers Appeal Committee of Securities and Futures Commission, Hong Kong, Deputy Convenor of the Listing Committee of the Hong Kong Stock Exchange and a council member of the Hong Kong Stock Exchange. He also served as Honorary Chief Executive Officer of The Chamber of Hong Kong Listed Companies Limited. Currently, he is a Vice Chairman of The Chamber of Hong Kong Listed Companies. Mr. Sun graduated from the Wharton School of the University of Pennsylvania, the United States, with a Bachelor of Science in Economics degree in economics in 1981. Mr. Sun also completed the Stanford Executive Program of Stanford Business School, the Unites States, in 2000. Mr. Sun has been a fellow, since April 1992, of the Association of Chartered Certified Accountants (formerly the Chartered Association of Certified Accountants), the United Kingdom, and a fellow of the Hong Kong Institute of Certified Public Accountants (formerly the Hong Kong Society of Accountants) since November 2009.

Tze Shan Hailson Yu

Mr. Yu Tze Shan Hailson is an Independent Non-Executive Director of the Company. He graduated from Department of Electrical Engineering of the University of Calgary, Canada with a bachelor’s degree in engineering in 1979, the University of Hong Kong with a master’s degree in electrical engineering in 1987 and City University of Hong Kong with a Master’s degree of law in Arbitration and Dispute Resolution in 1995, and completed a postgraduate diploma in investment management and graduate certificates in Hong Kong Laws and Traditional Chinese Medicine. Mr. Yu served as equipment maintenance and testing engineer, equipment maintenance and testing laboratory manager, computer engineering and systems engineering manager of Ampex Ferrotec Limited in Hong Kong successively from June 1979 to September 1987. He joined China International Trust & Investment Corporation Hong Kong (Holdings) Limited and served as general manager of engineering research and development department and consultant of Petroleum Development and LPG Tank Terminal Port successively from October 1987 to January 1998. He has been serving as deputy managing director of Versitech Limited, and deputy director of Technology Transfer Office of the University of Hong Kong since February 1998. Since November 2013, Mr. Yu has been serving as an independent non-executive director of China Traditional Chinese Medicine Holdings Co., Limited formerly known as Winteam Pharmaceutical Group Limited, a company listed on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) (stock code: 570)). He has also been serving as an independent non-executive director of Sinopharm Group Co. Ltd., a company listed on the Stock Exchange (stock code: 1099) since September 2014. Mr. Yu is currently a Charted Engineer, fellow of each of the Institute of Electrical Engineers, Hong Kong Institution of Engineers, the Chartered Institute of Arbitrators and Hong Kong Institute of Arbitrators.

Basic Compensation